专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110301188A1 Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents 有权
标题翻译：鞘氨醇-1-磷酸受体拮抗剂与抗微管剂之间的协同作用
公开(公告)号：US20110301188A1
公开(公告)日：2011-12-08
申请号：US13124586
申请日：2009-10-16
申请人： Geetha Shankar , Frauke Bentzien , Peter Lamb , David Matthews
发明人： Geetha Shankar , Frauke Bentzien , Peter Lamb , David Matthews
IPC分类号： A61K31/475 , A61P35/00 , A61P35/02 , A61K31/4192
CPC分类号： A61K31/4196 , A61K31/16 , A61K31/337 , A61K31/34 , A61K31/4192 , A61K31/435 , A61K2300/00
摘要： This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
摘要翻译：本发明基于以下发现：施用鞘氨醇-1-磷酸受体拮抗剂（S1P）和选自抗微管剂组的至少一种化学治疗剂提供了对于癌症的意想不到的优异治疗。抗菌剂如紫杉烷化合物是本领域已知的，例如紫杉醇（可从Bristol-Myers Squibb，Princeton，NJ获得），多西紫杉醇（可从Sanofi-aventis，Bridgewater，NJ获得）和类似物和其它作为抗微管剂的化合物，如长春新碱（ONCVIN®，VINCASARPFS®，VCR），长春花碱（VELBAN®，VELSAR）和长春瑞滨等）和类似化合物。本发明还提供了通过施用治疗有效量的至少一种鞘氨醇-1-磷酸1（S1P1R）受体拮抗剂和至少一种抗微管剂来调节所选细胞群体如癌细胞的生长的方法。

2. 发明授权

US08802692B2 Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents 有权
标题翻译：鞘氨醇-1-磷酸受体拮抗剂和抗微管剂之间的协同作用
公开(公告)号：US08802692B2
公开(公告)日：2014-08-12
申请号：US13124586
申请日：2009-10-16
申请人： Geetha Shankar , Frauke Bentzien , Peter Lamb , David Matthews
发明人： Geetha Shankar , Frauke Bentzien , Peter Lamb , David Matthews
IPC分类号： A61K31/44 , A01N43/36 , A61K31/40
CPC分类号： A61K31/4196 , A61K31/16 , A61K31/337 , A61K31/34 , A61K31/4192 , A61K31/435 , A61K2300/00
摘要： This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
摘要翻译：本发明基于以下发现：施用鞘氨醇-1-磷酸受体拮抗剂（S1P）和选自抗微管剂组的至少一种化学治疗剂提供了对于癌症的意想不到的优异治疗。抗菌剂如紫杉烷化合物是本领域已知的，例如紫杉醇（可从Bristol-Myers Squibb，Princeton，NJ获得），多西紫杉醇（可从Sanofi-aventis，Bridgewater，NJ获得）和类似物和其它作为抗微管剂的化合物，如长春新碱（ONCVIN®，VINCASARPFS®，VCR），长春花碱（VELBAN®，VELSAR）和长春瑞滨等）和类似化合物。本发明还提供了通过施用治疗有效量的至少一种鞘氨醇-1-磷酸1（S1P1R）受体拮抗剂和至少一种抗微管剂来调节所选细胞群体如癌细胞的生长的方法。

3. 发明申请

US20050113283A1 Methods of treating conditions associated with an EDG-4 receptor 审中-公开
标题翻译：治疗与EDG-4受体相关的病症的方法
公开(公告)号：US20050113283A1
公开(公告)日：2005-05-26
申请号：US10390429
申请日：2003-03-14
申请人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
发明人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
IPC分类号： A61K31/00 , A61K31/137 , A61K31/17 , A61K31/381 , A61K31/4015 , A61K31/403 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4184 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/4418 , A61K31/472 , A61K31/495 , A61K31/513 , A61K31/53
CPC分类号： A61K31/4418 , A61K31/00 , A61K31/137 , A61K31/17 , A61K31/381 , A61K31/4015 , A61K31/403 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4184 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/472 , A61K31/495 , A61K31/513 , A61K31/53
摘要： The present invention provides a method of modulating an Edg-4 receptor mediated biological activity in a cell. A cell expressing the Edg-4 receptor is contacted with a modulator of an Edg-4 receptor sufficient to modulate the Edg-4 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-4 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-4 receptor is administered to the subject.
摘要翻译：本发明提供调节细胞中Edg-4受体介导的生物活性的方法。表达Edg-4受体的细胞与足以调节Edg-4受体介导的生物活性的Edg-4受体的调节剂接触。另一方面，本发明提供调节受试者中Edg-4受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-4受体的调节剂。

4. 发明申请

US20050261298A1 Methods of treating conditions associated with an Edg-7 receptor 审中-公开
标题翻译：治疗与Edg-7受体相关的病症的方法
公开(公告)号：US20050261298A1
公开(公告)日：2005-11-24
申请号：US10390428
申请日：2003-03-14
申请人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
发明人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
IPC分类号： A61K31/165 , A61K31/382 , A61K31/426 , A61K31/455 , A61K31/4709 , A61K31/498
CPC分类号： A61K31/165 , A61K31/382 , A61K31/426 , A61K31/455 , A61K31/4709 , A61K31/498
摘要： In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.
摘要翻译：一方面，本发明提供了调节细胞中Edg-7受体介导的生物活性的方法。表达Edg-7受体的细胞与能够调节Edg-7受体介导的生物活性的Edg-7受体的调节剂接触。另一方面，本发明提供了调节受试者中Edg-7受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-7受体的调节剂。

5. 发明申请

US20070032459A1 METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR 失效
标题翻译：治疗与EDG-3受体相关的病症的方法
公开(公告)号：US20070032459A1
公开(公告)日：2007-02-08
申请号：US10390426
申请日：2003-03-14
申请人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
发明人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
IPC分类号： A61K31/655 , A61K31/47 , A61K31/513 , A61K31/4745 , A61K31/445 , A61K31/4245 , A61K31/353
CPC分类号： A61K31/353 , A61K31/4245 , A61K31/445 , A61K31/47 , A61K31/4745 , A61K31/513 , A61K31/655
摘要： In one aspect, the present invention provides a method of modulating an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-3 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-3 receptor is administered to the subject. In yet another aspect, compounds and composition useful for modulation of the Edg-3 receptor are presented.
摘要翻译：一方面，本发明提供调节细胞中Edg-3受体介导的生物活性的方法。将表达Edg-3受体的细胞与Edg-3受体的调节剂接触，足以调节Edg-3受体介导的生物活性。另一方面，本发明提供了调节受试者中Edg-3受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-3受体的调节剂。在另一方面，提供了可用于调节Edg-3受体的化合物和组合物。

6. 发明授权

US07208502B2 Methods of treating conditions associated with an Edg-3 receptor 失效
标题翻译：治疗与Edg-3受体相关的病症的方法
公开(公告)号：US07208502B2
公开(公告)日：2007-04-24
申请号：US10390426
申请日：2003-03-14
申请人： David Solow-Cordero , Geetha Shankar , Juliet V. Spencer , Charles Gluchowski
发明人： David Solow-Cordero , Geetha Shankar , Juliet V. Spencer , Charles Gluchowski
IPC分类号： A61K31/47
CPC分类号： A61K31/353 , A61K31/4245 , A61K31/445 , A61K31/47 , A61K31/4745 , A61K31/513 , A61K31/655
摘要： In one aspect, the present invention provides a method of modulating an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-3 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-3 receptor is administered to the subject. In yet another aspect, compounds and composition useful for modulation of the Edg-3 receptor are presented.
摘要翻译：一方面，本发明提供调节细胞中Edg-3受体介导的生物活性的方法。将表达Edg-3受体的细胞与Edg-3受体的调节剂接触，足以调节Edg-3受体介导的生物活性。另一方面，本发明提供了调节受试者中Edg-3受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-3受体的调节剂。在另一方面，提供了可用于调节Edg-3受体的化合物和组合物。

7. 发明授权

US07063966B2 Chimeric G protein coupled receptors 失效
标题翻译：嵌合G蛋白偶联受体
公开(公告)号：US07063966B2
公开(公告)日：2006-06-20
申请号：US09904099
申请日：2001-07-11
申请人： Geetha Shankar , Jason N. Munning , Juliet V. Spencer
发明人： Geetha Shankar , Jason N. Munning , Juliet V. Spencer
IPC分类号： C07K17/705 , C07K19/00 , C12N15/62
CPC分类号： G01N33/74 , C07K14/705 , C07K2319/00 , G01N2500/04
摘要： The present invention provides chimeric Edg receptors, useful as components of an assay system. The present invention also provide methods of screening for compounds that bind a chimeric Edg receptor, for example, by contacting a chimeric Edg receptor with a compound and detecting a change in chimeric Edg receptor-mediated activity such as calcium mobilization.
摘要翻译：本发明提供了可用作测定系统的组分的嵌合Edg受体。本发明还提供了筛选结合嵌合Edg受体的化合物的方法，例如通过使嵌合Edg受体与化合物接触并检测嵌合Edg受体介导的活性如钙动员的变化。

8. 发明申请

US20050101518A1 Methods of treating conditions associated with an EDG-2 receptor 审中-公开
标题翻译：治疗与EDG-2受体相关的病症的方法
公开(公告)号：US20050101518A1
公开(公告)日：2005-05-12
申请号：US10390427
申请日：2003-03-14
申请人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
发明人： David Solow-Cordero , Geetha Shankar , Juliet Spencer , Charles Gluchowski
IPC分类号： A61K31/00 , A61K31/137 , A61K31/17 , A61K31/381 , A61K31/4015 , A61K31/403 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4184 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/4418 , A61K31/472 , A61K31/495 , A61K31/513 , A61K31/53
CPC分类号： A61K31/17 , A61K31/00 , A61K31/137 , A61K31/381 , A61K31/4015 , A61K31/403 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4164 , A61K31/4184 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/4418 , A61K31/472 , A61K31/495 , A61K31/513 , A61K31/53
摘要： In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biological activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biological activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.
摘要翻译：一方面，本发明提供了调节细胞中Edg-2受体介导的生物活性的方法。表达Edg-2受体的细胞与调节Edg-2受体介导的生物活性的Edg-2受体的调节剂接触。另一方面，本发明提供了调节受试者中Edg-2受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-2受体的调节剂。

9. 发明申请

US20050065194A1 Methods of treating conditions associated with an Edg-2 receptor 审中-公开
标题翻译：治疗与Edg-2受体相关的病症的方法
公开(公告)号：US20050065194A1
公开(公告)日：2005-03-24
申请号：US10760061
申请日：2004-01-16
申请人： Geetha Shankar , David Solow-Cordero , Juliet Spencer , Charles Gluchowski
发明人： Geetha Shankar , David Solow-Cordero , Juliet Spencer , Charles Gluchowski
IPC分类号： A61K31/433 , C07D285/14
CPC分类号： A61K31/433
摘要： In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biological activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biological activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.
摘要翻译：一方面，本发明提供了调节细胞中Edg-2受体介导的生物活性的方法。表达Edg-2受体的细胞与调节Edg-2受体介导的生物活性的Edg-2受体的调节剂接触。另一方面，本发明提供了调节受试者中Edg-2受体介导的生物活性的方法。向受试者施用治疗有效量的Edg-2受体的调节剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式